These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S. Circulation; 1994 Jan; 89(1):68-75. PubMed ID: 8281697 [Abstract] [Full Text] [Related]
6. [Effect of captopril on mortality and morbidity in patients with dysfunction of the left ventricle after myocardial infarction. Results on survival and hypertrophic studies]. Pfeffer MA, Braunvald Iu, Moĭe LA, Basta L, Braun EDzh, Kaddi TE, Dévis BR, Geltman EM, Goldman S, Fleĭker GS. Kardiologiia; 1993 Jan; 33(12):14-23, 3. PubMed ID: 7910865 [Abstract] [Full Text] [Related]
8. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, Arnold JM, Moyé L, Pfeffer M. J Am Coll Cardiol; 1997 Feb; 29(2):229-36. PubMed ID: 9014971 [Abstract] [Full Text] [Related]
10. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Borghi C, Ambrosioni E, Survival of Myocardial Infarction Long-term Evaluation Study Group. Am Heart J; 2007 Mar; 153(3):445.e7-14. PubMed ID: 17307427 [Abstract] [Full Text] [Related]
13. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. Thune JJ, Signorovitch JE, Kober L, McMurray JJ, Swedberg K, Rouleau J, Maggioni A, Velazquez E, Califf R, Pfeffer MA, Solomon SD. Eur J Heart Fail; 2011 Feb; 13(2):148-53. PubMed ID: 21037250 [Abstract] [Full Text] [Related]
14. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, Chertow GM, Moyé LA, Pfeffer MA, Solomon SD. Circulation; 2004 Dec 14; 110(24):3667-73. PubMed ID: 15569840 [Abstract] [Full Text] [Related]
18. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. Hager WD, Davis BR, Riba A, Moye LA, Wun CC, Rouleau JL, Lamas GA, Pfeffer MA. Am Heart J; 1998 Mar 14; 135(3):406-13. PubMed ID: 9506325 [Abstract] [Full Text] [Related]
19. Ventricular arrhythmias in the acute and chronic phases after acute myocardial infarction. Effect of intervention with captopril. Søgaard P, Gøtzsche CO, Ravkilde J, Nørgaard A, Thygesen K. Circulation; 1994 Jul 14; 90(1):101-7. PubMed ID: 8025983 [Abstract] [Full Text] [Related]